View in EDS HTML Full Text PDF Full Text

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.

Saved in:
Bibliographic Details
Title: Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.
Authors: Ingram, John R.1,2 (AUTHOR) ingramjr@cardiff.ac.uk, Fujita, Hideki3 (AUTHOR), Gottlieb, Alice B.4 (AUTHOR), Lev-Tov, Hadar5 (AUTHOR), Prens, Errol2,6 (AUTHOR), Sayed, Christopher J.2,7 (AUTHOR), Shi, Vivian Y.8 (AUTHOR), Szepietowski, Jacek C.2,9,10 (AUTHOR), Takahashi, Kenzo11 (AUTHOR), Frew, John W.12,13,14 (AUTHOR), Lambert, Jérémy15 (AUTHOR), Davis, Leah16 (AUTHOR), Oh, Tae17 (AUTHOR), Rolleri, Robert16 (AUTHOR), Saintmard, Marie-Hélène15 (AUTHOR), Orenstein, Lauren A. V.18 (AUTHOR)
Source: Pain & Therapy. Dec2025, Vol. 14 Issue 6, p1861-1878. 18p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938237
DOI:10.1007/s40122-025-00779-7